Product image of Yesafili (Aflibercept) supplied by GNH India

Yesafili

Active Ingredient:
Aflibercept
Origin:
EU

Yesafili (Aflibercept)

Yesafili (aflibercept) is an intravitreal injection used to treat retinal conditions like wet age-related macular degeneration and diabetic macular edema. This biosimilar offers a cost-effective alternative for eye health support. Suitable for patients requiring vascular endothelial growth factor inhibition. Short-term supply for ongoing treatment plans.

Manufacturer / TM Owner

Biosimilar Collaborations Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • Yesafili (aflibercept) is prescribed to address retinal disorders caused by abnormal blood vessel growth. It helps reduce fluid leakage and swelling in the macula, supporting vision maintenance. Commonly used for wet age-related macular degeneration and diabetic macular edema. Also indicated for macular edema following retinal vein occlusion. Works by blocking VEGF pathways in the eye.

Side Effects

  • Patients may notice improved or stabilized vision after treatment with Yesafili. Some experience temporary eye discomfort or redness at the injection site. Blurred vision for a few days post-injection is common. Eye floaters or flashes may occur but typically resolve over time. Regular follow-up appointments help monitor progress.

Precautions & Warnings

  • Store unopened vials refrigerated between 2°C and 8°C. Protect from light and avoid freezing. Use within 24 hours of opening if handled aseptically. Discard any unused portion. Inform your healthcare provider of eye infections or recent eye surgeries. Avoid rubbing the eye post-injection to prevent irritation.

Avoid Interactions

  • No known direct drug interactions with systemic medications. Caution advised with other intravitreal therapies due to additive effects. Concomitant use of anticoagulants may increase bleeding risk in the eye. Alcohol consumption may exacerbate eye dryness or irritation. Always disclose all medications to your healthcare provider before treatment.

Frequently Asked Questions

Yesafili is used to treat retinal conditions such as wet age-related macular degeneration and diabetic macular edema.

Yesafili is given as an intravitreal injection directly into the eye by a healthcare professional.

Consult your doctor if you have known allergies to aflibercept or similar medications before use.

Common effects include eye discomfort, redness, blurred vision, or floaters after injection.

Yes, Yesafili is a biosimilar to the reference product Eylea (aflibercept).

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Aflibercept

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT